{"transactions":[{"id":748747,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-06T00:02:04.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":16875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting."}],"balance_after":27535,"source":{"system":"sec-edgar","filing":"0001193125-26-260246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526260246/ownership.xml","form_type":"4"}},{"id":962598,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Senior Notes","published_at":"2025-12-19T21:40:45.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"reported_value":20000000,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the \"2027 Notes\") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the \"2030 Notes\") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the \"2027 Notes\") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the \"2030 Notes\") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."}],"derivative":{"exercise_price":60,"underlying":"Common Stock","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0001193125-25-326980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000119312525326980/ownership.xml","form_type":"4"}},{"id":962597,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Senior Notes","published_at":"2025-12-19T21:40:45.000Z","date":"2025-12-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"reported_value":20000000,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the \"2027 Notes\") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the \"2030 Notes\") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the \"2027 Notes\") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the \"2030 Notes\") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."}],"derivative":{"exercise_price":141.97,"underlying":"Common Stock","underlying_shares":140875},"source":{"system":"sec-edgar","filing":"0001193125-25-326980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000119312525326980/ownership.xml","form_type":"4"}},{"id":1213621,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-03-12T00:00:17.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4792,"derivative":{"exercise_price":99.69,"exercise_date":"2026-03-10","expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0000950170-25-037531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017025037531/ownership.xml","form_type":"4"}},{"id":1213620,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-12T00:00:17.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":2383,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026."}],"balance_after":10660,"source":{"system":"sec-edgar","filing":"0000950170-25-037531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017025037531/ownership.xml","form_type":"4"}},{"id":1428319,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T12:00:04.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":5648,"price":134.66,"value":760559.68,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":284034,"source":{"system":"sec-edgar","filing":"0000950170-24-098859","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024098859/ownership.xml","form_type":"4"}},{"id":1428318,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T12:00:04.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":18284,"price":134.06,"value":2451153.04,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":278386,"source":{"system":"sec-edgar","filing":"0000950170-24-098859","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024098859/ownership.xml","form_type":"4"}},{"id":1428317,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T12:00:04.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":13106,"price":133.07,"value":1744015.42,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":260102,"source":{"system":"sec-edgar","filing":"0000950170-24-098859","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024098859/ownership.xml","form_type":"4"}},{"id":1599788,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-06T01:00:28.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":3679,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3679,"derivative":{"exercise_price":128.67,"exercise_date":"2025-03-01","expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":3679},"source":{"system":"sec-edgar","filing":"0000950170-24-026613","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024026613/ownership.xml","form_type":"4"}},{"id":1599787,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-06T01:00:28.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":1846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025."}],"balance_after":8277,"source":{"system":"sec-edgar","filing":"0000950170-24-026613","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024026613/ownership.xml","form_type":"4"}},{"id":1807816,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-15T12:00:10.000Z","date":"2023-08-14","kind":"purchase","planned":false,"acquired":true,"shares":4032,"price":109.89,"value":443076.48,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $109.67 to $110, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":246996,"source":{"system":"sec-edgar","filing":"0001209191-23-045766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123045766/doc4.xml","form_type":"4"}},{"id":1807815,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-15T12:00:10.000Z","date":"2023-08-14","kind":"purchase","planned":false,"acquired":true,"shares":5947,"price":109.19,"value":649352.93,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":242964,"source":{"system":"sec-edgar","filing":"0001209191-23-045766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123045766/doc4.xml","form_type":"4"}},{"id":1809140,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T12:00:08.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":23686,"price":108.05,"value":2559272.3,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.70 to $108.48, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":237017,"source":{"system":"sec-edgar","filing":"0001209191-23-045498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123045498/doc4.xml","form_type":"4"}},{"id":1810325,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T11:40:04.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":31570,"price":106.26,"value":3354628.2,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.01 to $106.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":213331,"source":{"system":"sec-edgar","filing":"0001209191-23-045366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123045366/doc4.xml","form_type":"4"}},{"id":1810324,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T11:40:04.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":1091,"price":105.9,"value":115536.9,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105 to $106, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":181761,"source":{"system":"sec-edgar","filing":"0001209191-23-045366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123045366/doc4.xml","form_type":"4"}},{"id":1810323,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T11:40:04.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":2206,"price":104.67,"value":230902.02,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.99 to $104.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":180670,"source":{"system":"sec-edgar","filing":"0001209191-23-045366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123045366/doc4.xml","form_type":"4"}},{"id":1964289,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T01:00:46.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":3257,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3257,"derivative":{"exercise_price":155.99,"exercise_date":"2024-03-06","expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":3257},"source":{"system":"sec-edgar","filing":"0001209191-23-017406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123017406/doc4.xml","form_type":"4"}},{"id":1964288,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T01:00:46.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":1523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024."}],"balance_after":6431,"source":{"system":"sec-edgar","filing":"0001209191-23-017406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919123017406/doc4.xml","form_type":"4"}},{"id":2158835,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T12:00:25.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":6250,"price":105.16,"value":657250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.085 to $105.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":108178,"source":{"system":"sec-edgar","filing":"0001209191-22-050002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122050002/doc4.xml","form_type":"4"}},{"id":2158834,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T12:00:25.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":30106,"price":104.67,"value":3151195.02,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $104.065 to $105.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":101928,"source":{"system":"sec-edgar","filing":"0001209191-22-050002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122050002/doc4.xml","form_type":"4"}},{"id":2158833,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T12:00:25.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":20744,"price":103.87,"value":2154679.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.06 to $104.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":71822,"source":{"system":"sec-edgar","filing":"0001209191-22-050002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122050002/doc4.xml","form_type":"4"}},{"id":2159677,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Senior Notes","published_at":"2022-09-14T12:00:13.000Z","date":"2022-09-13","kind":"grant","acquired":true,"price":20000000,"reported_value":20000000,"ownership":{"direct":false,"nature":"By Revocable Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the \"2027 Notes\") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the \"2027 Notes\") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election."}],"derivative":{"exercise_price":141.97,"underlying":"Common Stock","underlying_shares":140879},"source":{"system":"sec-edgar","filing":"0001209191-22-049820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122049820/doc4.xml","form_type":"4"}},{"id":2177390,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T12:30:47.000Z","date":"2022-08-19","kind":"purchase","acquired":true,"shares":6060,"price":108.8,"value":659328.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.57 to $109.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":51078,"source":{"system":"sec-edgar","filing":"0001209191-22-046973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122046973/doc4.xml","form_type":"4"}},{"id":2177389,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T12:30:47.000Z","date":"2022-08-19","kind":"purchase","acquired":true,"shares":40110,"price":108.2,"value":4339902.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.56 to $108.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":45018,"source":{"system":"sec-edgar","filing":"0001209191-22-046973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122046973/doc4.xml","form_type":"4"}},{"id":2243119,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-07T00:22:56.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":8329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in three equal annual installments beginning June 2, 2023."}],"balance_after":8329,"derivative":{"exercise_price":72.58,"exercise_date":"2023-06-02","expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":8329},"source":{"system":"sec-edgar","filing":"0001209191-22-034739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122034739/doc4.xml","form_type":"4"}},{"id":2243118,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":41120,"kind":"person","name":"Chambers Michael Andrew","position":1,"cik":"0001932527","reported_name":"Chambers Michael Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T00:22:56.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning June 2, 2023."}],"balance_after":4908,"source":{"system":"sec-edgar","filing":"0001209191-22-034739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122034739/doc4.xml","form_type":"4"}}]}